{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:52:59Z","timestamp":1776401579303,"version":"3.51.2"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background:<\/jats:title><jats:p>Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the above-mentioned indication, as well as for patients with<jats:italic>BRCA<\/jats:italic>-mutated Pt-S or platinum-resistant (Pt-R) OC and no therapeutic alternatives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In this observational, retrospective study we analysed the efficacy and safety of rucaparib within the RAP in Spain. Hospitals associated with the Spanish Ovarian Cancer Research Group (GEICO) recruited patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer treated with rucaparib 600\u00a0mg twice daily as maintenance or treatment (Pt-S\/Pt-R) in the RAP. Baseline characteristics, efficacy, and safety data were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Between July 2020 and February 2021, 51 patients treated in 22 hospitals in the RAP were included in the study. Eighteen patients with a median of 3 (range, 1\u20136) prior treatment lines received rucaparib as maintenance; median progression-free survival (PFS) for this group was 9.1 months (95% confidence interval [CI], 4.2\u201311.6 months). Among 33 patients (median 5 [range, 1\u20139] prior treatment lines) who received rucaparib as treatment, 7 and 26 patients had Pt-S and Pt-R disease, respectively. Median PFS was 10.6 months (95% CI, 2.5 months-not reached) in the Pt-S group and 2.2 months (95% CI, 1.1\u20133.2 months) in the Pt-R group. Grade\u2009\u2265\u20093 treatment-emergent adverse events were reported in 39% of all patients, the most common being anaemia (12% and 15% in the maintenance and treatment groups, respectively). At data cut-off, 5 patients remained on treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Efficacy results in these heavily pre-treated patients were similar to those from previous trials. The safety profile of rucaparib in real life was predictable and manageable.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12885-022-10191-5","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T19:04:38Z","timestamp":1667934278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain \u2013 A GEICO study"],"prefix":"10.1186","volume":"22","author":[{"given":"Alfonso","family":"Yubero","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aranzazu","family":"Barqu\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purificaci\u00f3n","family":"Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Pajares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piedad","family":"Reche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Calzas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Gaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Fuentes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Salvador","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Manso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Taus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"M\u00e1rquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Madani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Marquina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Constenla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Dosil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"issue":"3","key":"10191_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10191_CR2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s12094-020-02545-x","volume":"23","author":"A Redondo","year":"2021","unstructured":"Redondo A, Guerra E, Manso L, et al. SEOM clinical guideline in ovarian cancer (2020). Clin Transl Oncol. 2021;23(5):961\u20138.","journal-title":"Clin Transl Oncol"},{"issue":"7","key":"10191_CR3","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/ijgc-2020-001288","volume":"30","author":"A Madariaga","year":"2020","unstructured":"Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020;30(7):903\u201315.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10191_CR4","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jnci\/djq509","volume":"103","author":"Y Drew","year":"2011","unstructured":"Drew Y, Mulligan EA, Vong WT, et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334\u201346.","journal-title":"J Natl Cancer Inst"},{"issue":"10106","key":"10191_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949\u201361.","journal-title":"Lancet"},{"issue":"2","key":"10191_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","volume":"147","author":"AM Oza","year":"2017","unstructured":"Oza AM, Tinker AV, Oaknin A, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017;147(2):267\u201375.","journal-title":"Gynecol Oncol"},{"key":"10191_CR7","unstructured":"Rubraca (rucaparib) Summary of Product Characteristics; available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/rubraca-epar-product-information_en.pdf. Accessed 21 September 2022."},{"issue":"9","key":"10191_CR8","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/ijgc-2019-000623","volume":"29","author":"RS Kristeleit","year":"2019","unstructured":"Kristeleit RS, Oaknin A, Ray-Coquard I, et al. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. Int J Gynecol Cancer. 2019;29(9):1396\u2013404.","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10191_CR9","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S1470-2045(22)00122-X","volume":"23","author":"R Kristeleit","year":"2022","unstructured":"Kristeleit R, Lisyanskaya A, Fedenko A, et al. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(4):465\u201378.","journal-title":"Lancet Oncol"},{"key":"10191_CR10","unstructured":"Clovis Oncology initiates. early access program for rucaparib as treatment and as maintenance therapy in recurrent ovarian cancer in Europe. https:\/\/www.businesswire.com\/news\/home\/20180323005344\/en\/Clovis-Oncology-Initiates-Early-Access-Program-Rucaparib. [accessed 2022 10th February 2022]."},{"issue":"5","key":"10191_CR11","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/S1470-2045(20)30061-9","volume":"21","author":"JA Ledermann","year":"2020","unstructured":"Ledermann JA, Oza AM, Lorusso D, et al. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(5):710\u201322.","journal-title":"Lancet Oncol"},{"issue":"9","key":"10191_CR12","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274\u201384.","journal-title":"Lancet Oncol"},{"issue":"22","key":"10191_CR13","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154\u201364.","journal-title":"N Engl J Med"},{"issue":"1","key":"10191_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ygyno.2019.10.023","volume":"156","author":"SC Cecere","year":"2020","unstructured":"Cecere SC, Giannone G, Salutari V, et al. Olaparib as maintenance therapy in patients with BRCA 1\u20132 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome. Gynecol Oncol. 2020;156(1):38\u201344.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10191_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13048-019-0594-1","volume":"12","author":"J Ni","year":"2019","unstructured":"Ni J, Cheng X, Zhou R, Xu X, Guo W, Chen X. Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. J Ovarian Res. 2019;12(1):117.","journal-title":"J Ovarian Res"},{"issue":"5","key":"10191_CR16","doi-asserted-by":"crossref","first-page":"e1180","DOI":"10.1002\/cnr2.1180","volume":"2","author":"Y Cao","year":"2019","unstructured":"Cao Y, Chen H, Huang Y, Hu H. Real-world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau. Cancer Rep (Hoboken). 2019;2(5):e1180.","journal-title":"Cancer Rep (Hoboken)"},{"issue":"36","key":"10191_CR17","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.2217\/fon-2019-0471","volume":"15","author":"JR Gallagher","year":"2019","unstructured":"Gallagher JR, Heap KJ, Carroll S, Travers K, Harrow B, Westin SN. Real-world adverse events with niraparib 200\u00a0mg\/day maintenance therapy in ovarian cancer: a retrospective study. Future Oncol. 2019;15(36):4197\u2013206.","journal-title":"Future Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-10191-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-10191-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T12:49:36Z","timestamp":1701348576000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-10191-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10191"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-10191-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"10 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee of HM Hospitales (Code: 20.05.1633-GHM) and performed according to the Declaration of Helsinki and local laws and regulations. Patients provided written informed consent. Informed consent was not required from inaccessible patients according to Spanish laws.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"AY: Consulting or advisory role: Clovis Oncology, GSK, AstraZeneca, MSD, PharmaMar, Roche. Travel, accommodation, expenses: MSD, GSK, PharmaMar.AB: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.PE: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.BP: Consulting or advisory role: Clovis Oncology, Novartis, AstraZeneca. Travel, accommodation: AstraZeneca.LS: Consulting or advisory role: GSK-Tesaro, Clovis Oncology, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.PR: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.JA: Consulting or advisory role: GSK, Clovis, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.JC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.LG: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.JF: Advisory Board: Roche, AstraZeneca, Clovis Oncology and GSK.AS: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology, Pfizer, Lilly, Novartis.CS: Consulting or advisory role: PharmaMar. Travel, accommodation, expenses: GSK, MSD, Pfizer, AstraZeneca.LM: Consulting or advisory role: Roche\/Genentech, AstraZeneca, Novartis, Pfizer, Tesaro, Eisai, Lilly, Clovis Oncology, Pierre Fabre, GlaxoSmithKline. Speakers\u2019 Bureau: Roche\/Genentech, Novartis, Pfizer, AstraZeneca, Lilly. Research Funding: Tesaro.AH: Principal investigator of clinical trials: AstraZeneca, Roche. Member of advisory boards: GSK. Personal fees: Clovis Oncology, GSK, MSD and PharmaMar.AT: Personal fees and non-financial support: Roche, BMS, MSD, GSK, AstraZeneca and Pfizer.RM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.JM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.MM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.GM: Consulting fees and honoraria for lectures, presentations, speaker bureaus: Roche, PharmaMar, GSK\/Tesaro, MSD, AstraZeneca, Clovis Oncology, Medicamenta, Lilly, Pfizer.VC: Consulting or advisory role: GSK, AstraZeneca, MSD, PharmaMar. Travel, accommodation, expenses: GSK, AstraZeneca, MSD, PharmaMar.MC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.MG: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.AD: Employee and owner of stock and stock options in Clovis Oncology, Inc.AGM: Advisory\/Consultancy: Alkermes, Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, macrogenmics, Novartis, Oncoinvent, Pfizer\/Merck, PharmaMar, Roche, Sotio, Sutro. Speaker Bureau: AstraZeneca, PharmaMar, Roche, GSK, Clovis Oncology. Research Grant\/Funding: Roche, TESARO: A GSK Company. Travel\/Accommodation\/Expenses: AstraZeneca, PharmaMar, Roche, TESARO: A GSK Company.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"1150"}}